Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash & Equivalents (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash & Equivalents for 7 consecutive years, with $357.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 196.88% to $357.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $357.0 million, a 196.88% increase, with the full-year FY2025 number at $357.0 million, up 196.88% from a year prior.
  • Cash & Equivalents was $357.0 million for Q4 2025 at Kymera Therapeutics, up from $112.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $357.0 million in Q4 2025 to a low of $33.7 million in Q1 2022.
  • A 5-year average of $125.2 million and a median of $89.2 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 56.21% in 2021, then skyrocketed 396.68% in 2025.
  • Kymera Therapeutics' Cash & Equivalents stood at $48.0 million in 2021, then skyrocketed by 42.56% to $68.4 million in 2022, then soared by 60.78% to $110.0 million in 2023, then grew by 9.36% to $120.3 million in 2024, then skyrocketed by 196.88% to $357.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Cash & Equivalents are $357.0 million (Q4 2025), $112.9 million (Q3 2025), and $335.8 million (Q2 2025).